Fulcrum Reports Positive 20 mg Dose Trial Results with 9.9% HbF Increase
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 06 2025
0mins
Should l Buy FULC?
Source: Globenewswire
- Significant Dose Response: In the 20 mg cohort, fetal hemoglobin (HbF) levels increased by an average of 9.9% at six weeks, compared to 5.6% in the 12 mg cohort, indicating a stronger therapeutic potential that could provide more effective treatment options for severe sickle cell disease patients.
- Positive Patient Response: 58% of patients in the 20 mg cohort achieved HbF levels ≥20%, which is associated with a reduction in annual vaso-occlusive crises (VOCs), highlighting the drug's significant impact on improving patient quality of life.
- Good Safety Profile: As of the November 11, 2025 data cutoff, pociredir has been administered to 148 adults with no reported treatment-related serious adverse events, demonstrating favorable tolerability and enhancing its credibility as a potential treatment option.
- Positive Future Outlook: Fulcrum plans to update trial results in Q1 2026, further validating the efficacy and safety of pociredir, which may drive its application in the sickle cell disease market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FULC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FULC
Wall Street analysts forecast FULC stock price to rise
11 Analyst Rating
9 Buy
1 Hold
1 Sell
Moderate Buy
Current: 10.860
Low
7.00
Averages
16.80
High
25.00
Current: 10.860
Low
7.00
Averages
16.80
High
25.00
About FULC
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fulcrum Therapeutics Grants Stock Options to New Employee
- Stock Options Granted: Fulcrum Therapeutics granted 70,000 stock options to a new employee at an exercise price of $10.72 per share, reflecting the company's commitment to attracting talent and strengthening its team to drive research and development efforts.
- Incentive Plan Context: The grant is made under the amended 2022 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4), which demonstrates the company's adherence to compliance and transparency in talent acquisition.
- Options Structure: These options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and an additional 6.25% vesting quarterly, designed to incentivize long-term employee retention and enhance engagement.
- Strategic Company Positioning: Fulcrum focuses on developing small molecules to improve the lives of patients with genetically defined rare diseases, particularly its lead program pociredir for sickle cell disease, showcasing the company's strategic positioning in areas of high unmet medical need.
See More
BMO Initiates Medline Coverage with $45 Price Target
- Medline Coverage Initiation: BMO Capital analyst Sean Dodge initiated coverage on Medline Inc (NASDAQ:MDLN) with an Outperform rating and a price target of $45, indicating an approximate 11% upside from the current share price of $40.52, reflecting confidence in the company's growth prospects.
- Hims & Hers Rating Update: Evercore ISI Group analyst Mark Mahaney initiated coverage on Hims & Hers Health Inc (NYSE:HIMS) with an In-Line rating and a price target of $33, suggesting a stable growth outlook as the current share price stands at $31.69.
- Andersen Group Coverage Initiation: UBS analyst Kevin Mcveigh initiated coverage on Andersen Group Inc (NYSE:ANDG) with a Buy rating and a price target of $28, indicating significant upside potential from the current price of $24.29, reflecting optimism about its market performance.
- Netflix Rating Update: HSBC analyst Mohammed Khallouf initiated coverage on Netflix Inc (NASDAQ:NFLX) with a Buy rating and a price target of $107, suggesting an approximate 19% upside from the current share price of $89.44, indicating confidence in its content strategy and market position.
See More
Fulcrum Grants 30,400 Stock Options to New Employees at $10.84 Exercise Price
- Employee Incentive Program: Fulcrum Therapeutics granted 30,400 stock options to three new employees under its 2022 Inducement Stock Incentive Plan at an exercise price of $10.84 per share, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in the rare disease sector.
- Option Structure: The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting quarterly, ensuring continued employee contribution during their tenure, which enhances team stability and execution capability.
- Market Reaction: Fulcrum's stock closed at $10.84 on the grant date, reflecting the company's confidence in future growth while enhancing employee ownership and morale through incentive measures, which can boost overall productivity.
- Strategic Implications: This option grant is not only an incentive for new hires but also a critical move by Fulcrum to leverage talent attraction and retention strategies to drive innovation and business expansion in the rapidly evolving biopharmaceutical industry.
See More
Fulcrum Therapeutics Launches $150 Million Public Offering to Fund R&D
- Offering Size: Fulcrum Therapeutics has announced a $150 million public offering aimed at funding its research and clinical trials, thereby accelerating the development of drugs for genetically defined rare diseases.
- Additional Option: The company also intends to grant underwriters a 30-day option to purchase an additional $22.5 million in shares, which will help adjust the financing scale based on market demand, enhancing fundraising flexibility.
- Use of Proceeds: The proceeds from the offering will primarily be used for general corporate purposes, including R&D expenses, clinical trials, and potential acquisitions, which will help Fulcrum expand its product pipeline and enhance market competitiveness.
- Market Condition Impact: The completion of this public offering will be subject to market and other conditions, and Fulcrum must navigate uncertainties related to stock price fluctuations and changing market environments, which could affect the implementation of its financing plans.
See More
Fulcrum Therapeutics Shares Surge Following Encouraging Sickle Cell Study Results
Stock Surge: Fulcrum Therapeutics Inc's stock is rising significantly following positive initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease.
Positive Trial Results: The trial showed a 9.9% increase in mean absolute fetal hemoglobin (HbF) at six weeks, with 58% of patients achieving HbF levels ≥20%, which is linked to a reduction in vaso-occlusive crises.
Analyst Upgrades: Several analysts have raised their price forecasts for Fulcrum Therapeutics, with HC Wainwright increasing it from $18 to $25, and Piper Sandler from $16 to $23, reflecting confidence in the company's prospects.
Current Stock Performance: As of the latest publication, Fulcrum Therapeutics' stock is up 9.66%, trading at $14.21.
See More
Monday's Top Sectors: Computer Peripherals and Pharmaceuticals
Market Performance: Drug shares have shown relative strength, increasing by approximately 1.9% overall, with notable gains from Wave Life Sciences and Fulcrum Therapeutics.
Stock Highlights: Wave Life Sciences surged by about 132.4%, while Fulcrum Therapeutics rose by approximately 62.2% on Monday.
Sector Leaders: The video highlights Monday's sector leaders, including Computer Peripherals and Drugs.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
See More
Fulcrum Therapeutics Grants Stock Options to New Employee
- Stock Options Granted: Fulcrum Therapeutics granted 70,000 stock options to a new employee at an exercise price of $10.72 per share, reflecting the company's commitment to attracting talent and strengthening its team to drive research and development efforts.
- Incentive Plan Context: The grant is made under the amended 2022 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4), which demonstrates the company's adherence to compliance and transparency in talent acquisition.
- Options Structure: These options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and an additional 6.25% vesting quarterly, designed to incentivize long-term employee retention and enhance engagement.
- Strategic Company Positioning: Fulcrum focuses on developing small molecules to improve the lives of patients with genetically defined rare diseases, particularly its lead program pociredir for sickle cell disease, showcasing the company's strategic positioning in areas of high unmet medical need.
See More
BMO Initiates Medline Coverage with $45 Price Target
- Medline Coverage Initiation: BMO Capital analyst Sean Dodge initiated coverage on Medline Inc (NASDAQ:MDLN) with an Outperform rating and a price target of $45, indicating an approximate 11% upside from the current share price of $40.52, reflecting confidence in the company's growth prospects.
- Hims & Hers Rating Update: Evercore ISI Group analyst Mark Mahaney initiated coverage on Hims & Hers Health Inc (NYSE:HIMS) with an In-Line rating and a price target of $33, suggesting a stable growth outlook as the current share price stands at $31.69.
- Andersen Group Coverage Initiation: UBS analyst Kevin Mcveigh initiated coverage on Andersen Group Inc (NYSE:ANDG) with a Buy rating and a price target of $28, indicating significant upside potential from the current price of $24.29, reflecting optimism about its market performance.
- Netflix Rating Update: HSBC analyst Mohammed Khallouf initiated coverage on Netflix Inc (NASDAQ:NFLX) with a Buy rating and a price target of $107, suggesting an approximate 19% upside from the current share price of $89.44, indicating confidence in its content strategy and market position.
See More
Fulcrum Grants 30,400 Stock Options to New Employees at $10.84 Exercise Price
- Employee Incentive Program: Fulcrum Therapeutics granted 30,400 stock options to three new employees under its 2022 Inducement Stock Incentive Plan at an exercise price of $10.84 per share, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in the rare disease sector.
- Option Structure: The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting quarterly, ensuring continued employee contribution during their tenure, which enhances team stability and execution capability.
- Market Reaction: Fulcrum's stock closed at $10.84 on the grant date, reflecting the company's confidence in future growth while enhancing employee ownership and morale through incentive measures, which can boost overall productivity.
- Strategic Implications: This option grant is not only an incentive for new hires but also a critical move by Fulcrum to leverage talent attraction and retention strategies to drive innovation and business expansion in the rapidly evolving biopharmaceutical industry.
See More
Fulcrum Therapeutics Launches $150 Million Public Offering to Fund R&D
- Offering Size: Fulcrum Therapeutics has announced a $150 million public offering aimed at funding its research and clinical trials, thereby accelerating the development of drugs for genetically defined rare diseases.
- Additional Option: The company also intends to grant underwriters a 30-day option to purchase an additional $22.5 million in shares, which will help adjust the financing scale based on market demand, enhancing fundraising flexibility.
- Use of Proceeds: The proceeds from the offering will primarily be used for general corporate purposes, including R&D expenses, clinical trials, and potential acquisitions, which will help Fulcrum expand its product pipeline and enhance market competitiveness.
- Market Condition Impact: The completion of this public offering will be subject to market and other conditions, and Fulcrum must navigate uncertainties related to stock price fluctuations and changing market environments, which could affect the implementation of its financing plans.
See More
Fulcrum Therapeutics Shares Surge Following Encouraging Sickle Cell Study Results
Stock Surge: Fulcrum Therapeutics Inc's stock is rising significantly following positive initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease.
Positive Trial Results: The trial showed a 9.9% increase in mean absolute fetal hemoglobin (HbF) at six weeks, with 58% of patients achieving HbF levels ≥20%, which is linked to a reduction in vaso-occlusive crises.
Analyst Upgrades: Several analysts have raised their price forecasts for Fulcrum Therapeutics, with HC Wainwright increasing it from $18 to $25, and Piper Sandler from $16 to $23, reflecting confidence in the company's prospects.
Current Stock Performance: As of the latest publication, Fulcrum Therapeutics' stock is up 9.66%, trading at $14.21.
See More
Monday's Top Sectors: Computer Peripherals and Pharmaceuticals
Market Performance: Drug shares have shown relative strength, increasing by approximately 1.9% overall, with notable gains from Wave Life Sciences and Fulcrum Therapeutics.
Stock Highlights: Wave Life Sciences surged by about 132.4%, while Fulcrum Therapeutics rose by approximately 62.2% on Monday.
Sector Leaders: The video highlights Monday's sector leaders, including Computer Peripherals and Drugs.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
See More
